The day of your injection and the first 48 hours

Most patients are surprised by how straightforward the appointment is. A ChondroFiller injection is delivered in an outpatient clinic setting — no operating theatre, no general anaesthetic, and no overnight stay. The procedure uses ultrasound or fluoroscopic guidance to position the needle precisely within the cartilage defect, so the collagen scaffold is placed where it is needed rather than distributed diffusely through the joint.

Once injected, the collagen solution self-gels within 3–5 minutes, bonding with the body's natural fibrin to form a stable matrix inside the defect. From that moment, the scaffold is fixed in place and the biological process begins. Intravenous antibiotic cover is included as standard, and before leaving the clinic a six-week follow-up appointment is booked.

The first 48 hours are usually unremarkable. Some patients notice mild soreness or a sense of fullness around the joint — this is a normal part of the early inflammatory healing response and reflects the joint reacting to the new scaffold rather than anything going wrong. It does not indicate treatment failure. Managing this with rest, elevation where practical, and over-the-counter analgesia as directed by the clinical team is generally sufficient. Most people return home the same day and resume light daily activity within a day or two.

Why the first six weeks matter most

The six weeks following the injection form the most critical window in the entire recovery arc. The collagen scaffold has gelled and bonded — but it is not yet anchored by the patient's own tissue. Loading the joint before that anchorage is established risks disrupting the matrix at precisely the moment when it needs to remain undisturbed.

Within days to weeks of injection, progenitor cells from the surrounding synovium and subchondral bone begin migrating into the scaffold — the process known as acellular matrix-induced chondrogenesis. These cells gradually differentiate into chondrocytes and start laying down new cartilage from the inside out. Activity restriction during this phase is not arbitrary caution; it is protection for a repair process that has already started.

The practical guidance for weeks one to six is to avoid weight-bearing on the affected joint while maintaining controlled, gentle movement to prevent stiffness. The distinction matters: immobility slows recovery; premature loading undermines it.

How long this restriction lasts depends on the joint involved. For smaller joints such as the thumb base or wrist, mechanical forces are far lower, and gentle movement may be appropriate after as little as one to two weeks. For the knee, hip, or ankle, the full six-week window is typically observed. Defect size and individual factors such as age and tissue quality also influence the pace — which is why the six-week follow-up serves as the first objective clinical checkpoint to confirm the scaffold is settling as expected, and to guide the transition to the next phase.

When physiotherapy begins and what it involves

Somewhere around the six-week mark — confirmed at the follow-up appointment — the emphasis shifts from protection to rebuilding. Formal physiotherapy begins in earnest, targeting the muscle atrophy and reduced joint stability that commonly accompany even a short period of restricted loading.

The scaffold, by this point, is integrating with surrounding tissue and populated with maturing progenitor cells. Guided mechanical stimulation now becomes an asset rather than a risk: progressive loading helps signal to differentiating chondrocytes what kind of tissue they are forming. This is why physiotherapy during weeks six to twelve is not supplementary to the treatment — it is part of how the scaffold's potential is realised.

Low-impact activities such as swimming and cycling are typically introduced during this window. They move the joint through a useful range and build cardiovascular fitness without the impact forces that could overload still-maturing tissue. The progression beyond that — increased resistance, weight-bearing exercise, and eventually sport-specific drills — is paced by how the joint is responding, not by a fixed calendar. A physiotherapist who can assess load tolerance directly will advance the programme sooner in a joint that is coping well and hold back in one that is not.

For smaller joints, where the protection phase may already have been shorter, the physiotherapy arc follows the same logic at an accelerated pace. Consistent engagement throughout this phase gives the scaffold the best mechanical environment to complete its work.

Getting back to everyday activity and low-level sport

Around months two to three, the recovery arc shifts from structured physiotherapy into functional daily life. Most patients are moving through normal activities without restriction by this point — climbing stairs, covering longer distances on foot, returning to lighter work commitments — and the joint is tolerating loads that would have been inadvisable six weeks earlier.

Jogging and sport-specific conditioning drills enter the programme during this phase, introduced progressively under the physiotherapist's direction. The timing is individual: some patients begin light jogging at around ten weeks; others need closer to the five- or six-month mark. Milestones are set by load tolerance and symptom response, not by the calendar alone, which means two patients with the same procedure on the same day may progress at meaningfully different rates — both correctly.

The objective picture during this window comes from imaging. MRI evidence taken in this period typically shows a reduction in bone marrow oedema and a diminishing periarticular effusion, confirming that the joint environment is settling. The scaffold continues to mature, with new chondrocytes gradually filling the defect and consolidating into cartilage-like tissue over the course of months rather than weeks.

Progress during this phase tends to accumulate steadily — a widening of capacity each fortnight rather than a sudden step-change. Consistent engagement with the physiotherapy programme, combined with objective markers such as increasing load tolerance and improving imaging, gives a more reliable picture of how recovery is tracking than day-to-day symptoms alone.

Return to sport and what outcome data shows

Knee patients in published series achieve approximately 30-point improvements in IKDC scores at 12 months — a threshold regarded as clinically meaningful in cartilage research. MOCART imaging scores in the same studies range from 70 to 87, indicating good-to-excellent defect fill at follow-up.

For patients who do not see themselves in knee-focused data, Corain et al. (2023) followed 43 patients who received a single ChondroFiller injection for thumb-base osteoarthritis. Both early- and advanced-stage groups recorded highly significant reductions in NRS pain scores and improvements on the DASH questionnaire at 30 days and 6 months, alongside measurable gains in grip and pincer strength — a reminder that the evidence base extends well beyond a single joint.

Full return to high-impact sport is generally achievable by months 6 to 12, though that range is not a guarantee. Defect size, joint type, and individual healing rate all influence when the final threshold is crossed. A physiotherapist tracking load tolerance and symptom response will set that milestone more accurately than any fixed calendar can.

By the end of year one to two, the scaffold is on course for complete resorption, replaced by the patient's own tissue. The biological process that began with cell migration in the early weeks is, by this point, mature.

On safety, ChondroFiller's reported complication rate is approximately 0%, with a reoperation rate of 3–8% — substantially lower than microfracture, which carries a reoperation rate of up to 41%, or ACI/MACI, where complication and reoperation rates reach up to 17% and 37% respectively. For most patients considering this pathway, the more practical question is not how to manage procedural risk but how to pace the return to the activities they want to resume.

Follow-up, monitoring, and what happens next

The follow-up rhythm extends well beyond the initial appointment. Once the scaffold has stabilised and physiotherapy is under way, clinical review shifts its focus to objective monitoring — how the joint is responding over time, not just in the early weeks.

For patients managing early-to-moderate osteoarthritis, a structured long-term programme is available: yearly MRI to track defect fill and joint health, combined with bi-annual top-up ChondroFiller injections to maintain the scaffold environment. This is not a requirement for every patient, but for those where sustained joint preservation is the goal, it provides a framework for staying ahead of deterioration rather than waiting for symptoms to return.

If symptoms shift unexpectedly at any point — a flare, a new mechanical symptom, or a change in how the joint feels under load — the right first call is to the treating clinician directly, not via a generic GP referral pathway.

By the two-year mark, many patients report that the joint has receded into the background: functional, manageable, and no longer shaping daily decisions. The scaffold has been fully resorbed; what remains is the patient's own tissue, doing the work the collagen matrix was designed to invite in.

Follow-up and ongoing care are managed through the London Cartilage Clinic on Harley Street, which delivers ChondroFiller — offered in the UK under the Liquid Cartilage™ brand — as the country's certified centre for this treatment. Assessments can be arranged at londoncartilage.com.